Back to Search
Start Over
Anatomical localization of Cav3.1 calcium channels and electrophysiological effects of T-type calcium channel blockade in the motor thalamus of MPTP-treated monkeys.
- Source :
-
Journal of neurophysiology [J Neurophysiol] 2016 Jan 01; Vol. 115 (1), pp. 470-85. Date of Electronic Publication: 2015 Nov 04. - Publication Year :
- 2016
-
Abstract
- Conventional anti-Parkinsonian dopamine replacement therapy is often complicated by side effects that limit the use of these medications. There is a continuing need to develop nondopaminergic approaches to treat Parkinsonism. One such approach is to use medications that normalize dopamine depletion-related firing abnormalities in the basal ganglia-thalamocortical circuitry. In this study, we assessed the potential of a specific T-type calcium channel blocker (ML218) to eliminate pathologic burst patterns of firing in the basal ganglia-receiving territory of the motor thalamus in Parkinsonian monkeys. We also carried out an anatomical study, demonstrating that the immunoreactivity for T-type calcium channels is strongly expressed in the motor thalamus in normal and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys. At the electron microscopic level, dendrites accounted for >90% of all tissue elements that were immunoreactive for voltage-gated calcium channel, type 3.2-containing T-type calcium channels in normal and Parkinsonian monkeys. Subsequent in vivo electrophysiologic studies in awake MPTP-treated Parkinsonian monkeys demonstrated that intrathalamic microinjections of ML218 (0.5 μl of a 2.5-mM solution, injected at 0.1-0.2 μl/min) partially normalized the thalamic activity by reducing the proportion of rebound bursts and increasing the proportion of spikes in non-rebound bursts. The drug also attenuated oscillatory activity in the 3-13-Hz frequency range and increased gamma frequency oscillations. However, ML218 did not normalize Parkinsonism-related changes in firing rates and oscillatory activity in the beta frequency range. Whereas the described changes are promising, a more complete assessment of the cellular and behavioral effects of ML218 (or similar drugs) is needed for a full appraisal of their anti-Parkinsonian potential.<br /> (Copyright © 2016 the American Physiological Society.)
- Subjects :
- Action Potentials drug effects
Animals
Basal Ganglia metabolism
Basal Ganglia ultrastructure
Calcium Channels, T-Type metabolism
Dendrites metabolism
Dendrites ultrastructure
Macaca mulatta
Neural Pathways drug effects
Neural Pathways physiology
Neural Pathways ultrastructure
Parkinsonian Disorders metabolism
Thalamus metabolism
Thalamus ultrastructure
Azabicyclo Compounds administration & dosage
Azabicyclo Compounds pharmacology
Benzamides administration & dosage
Benzamides pharmacology
Calcium Channel Blockers administration & dosage
Calcium Channels, T-Type physiology
Neurons drug effects
Neurons physiology
Parkinsonian Disorders physiopathology
Thalamus drug effects
Thalamus physiology
Subjects
Details
- Language :
- English
- ISSN :
- 1522-1598
- Volume :
- 115
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Journal of neurophysiology
- Publication Type :
- Academic Journal
- Accession number :
- 26538609
- Full Text :
- https://doi.org/10.1152/jn.00858.2015